Research progress in signalling pathway in diabetic nephropathy

Diabetes/Metabolism Research and Reviews

Volumn 31, Issue 3, 2015, Pages 221-233

  Ni, Wei Jian ^a   Tang, Li Qin ^a   Wei, Wei ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Glomerular mesangial cell; Podocyte; Renal fibrosis; Signalling pathway

Indexed keywords

CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STAT PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN;

ARTICLE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; EXTRACELLULAR MATRIX; GENETIC SUSCEPTIBILITY; GLOMERULUS; GLUCOSE METABOLISM; HEMODYNAMICS; HUMAN; INFLAMMATION; KIDNEY HYPERTROPHY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; DIABETIC NEPHROPATHIES; METABOLISM; PATHOLOGY;

DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION;

EID: 84924234007     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2568     Document Type: Article

References (107)

1. Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012; 59:A7: e1-e420.
2. Zelmanovitz T, Gerchman F, Balthazar AP, Thomazelli FC, Matos JD, Canani LH. Diabetic nephropathy. Diabetol Metab Syndr 2009; 1: 10-27.
3. Gonzalez SM, Thomas DB, Barisoni L, Fornoni A. Diabetic nephropathy: is it time yet for routine kidney biopsy? World J Diabetes 2013; 4: 245-255.
4. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52: 1036-1040.
5. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. Eur J Clin Invest 2004; 34: 785-796.
6. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972.
7. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007; 115: 69-84.
8. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001; 410: 37-40.
9. Maestroni A, Tentori F, Meregalli G, et al. Inhibition of MAP-kinase cascade normalizes the proliferation rate of fibroblasts from patients with Type 1 diabetes and nephropathy. J Diabetes Complications 2005; 19: 291-296.
10. De Borst MH, Prakash J, Melenhorst WB, et al. Glomerular and tubular induction of the transcription factor c-Jun in human renal disease. J Pathol 2007; 213: 219-228.
11. Lin CL, Wang FS, Kuo YR, et al. Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int 2006; 69: 1593-1600.
12. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000; 12: 1-13.
13. Muller R, Daniel C, Hugo C, et al. The mitogen-activated protein kinase p38 alpha regulates tubular damage in murine anti-glomerular basement membrane nephritis. PLoS One 2013; 8: e56316-e56327.
14. Fujita H, Omori S, Ishikura K, Hida M, Awazu M. ERK and p38 mediate high-glucose-induced hypertrophy and TGF-beta expression in renal tubular cells. Am J Physiol Renal Physiol 2004; 286: F120-F126.
15. Kang SW, Adler SG, Lapage J, Natarajan R. p38 MAPK and MAPK kinase 3/6 mRNA and activities are increased in early diabetic glomeruli. Kidney Int 2001; 60: 543-552.
16. Remy G, Risco AM, Inesta-Vaquera FA, et al. Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal 2010; 22: 660-667.
17. Polzer K, Soleiman A, Baum W, et al. Selective p38MAPK isoform expression and activation in antineutrophil cytoplasmatic antibody-associated crescentic glomerulonephritis: role of p38MAPKalpha. Ann Rheum Dis 2008; 67: 602-608.
18. Riad A, Unger D, Du J, et al. Chronic inhibition of p38MAPK improves cardiac and endothelial function in experimental diabetes mellitus. Eur J Pharmacol 2007; 554: 40-45.
19. Da CJ, Damasceno RS, Machado UF, Beloto-Silva O, Oliveira-Souza M. High glucose concentration stimulates NHE-1 activity in distal nephron cells: the role of the Mek/Erk1/2/p90 and p38MAPK signaling pathways. Cell Physiol Biochem 2014; 33: 333-343.
20. Price DM, Wloka MT, Chik CL, Ho AK. Mitogen-activated protein kinase phosphatase-1 (MKP-1) preferentially dephosphorylates p42/44MAPK but not p38MAPK in rat pinealocytes. J Neurochem 2007; 101: 1685-1693.
21. Hsieh TJ, Fustier P, Zhang SL, et al. High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003; 144: 4338-4349.
22. Burt DJ, Gruden G, Thomas SM, et al. P38 mitogen-activated protein kinase mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells. Diabetologia 2003; 46: 531-537.
23. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006; 55: 225-233.
24. Kang SW, Natarajan R, Shahed A, et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003; 14: 3178-3187.
25. Dai T, Natarajan R, Nast CC, et al. Glucose and diabetes: effects on podocyte and glomerular p38MAPK, heat shock protein 25, and actin cytoskeleton. Kidney Int 2006; 69: 806-814.
26. Deshpande SD, Putta S, Wang M, et al. Transforming growth factor-beta-induced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 2013; 62: 3151-3162.
27. Chen HL, Wan YG, Zhao Q, et al. Regulative mechanism of renal inflammatory-related p38MAPK signaling pathway in diabetic nephropathy and interventional effects of Chinese herbal medicine. Zhongguo Zhong Yao Za Zhi 2013; 38: 2268-2272.
28. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 433-442.
29. Zhao Q, Wan Y, Wang C, et al. Regulatory mechanism of p38MAPK signaling pathway on renal tissue inflammation in chronic kidney disease and interventional effect of traditional Chinese medicine. Zhongguo Zhong Yao Za Zhi 2012; 37: 1700-1704.
30. Karrasch T, Steinbrecher KA, Allard B, Baldwin AS, Jobin C. Wound-induced p38MAPK-dependent histone H3 phosphorylation correlates with increased COX-2 expression in enterocytes. J Cell Physiol 2006; 207: 809-815.
31. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002; 20: 55-72.
32. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005; 115: 1111-1119.
33. Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene 2007; 26: 3100-3112.
34. Takekawa M, Tatebayashi K, Saito H. Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. Mol Cell 2005; 18: 295-306.
35. Lim AK, Ma FY, Nikolic-Paterson DJ, et al. Evaluation of JNK blockade as an early intervention treatment for type 1 diabetic nephropathy in hypertensive rats. Am J Nephrol 2011; 34: 337-346.
36. McDonald PH, Chow CW, Miller WE, et al. Beta-arrestin 2: a receptor-regulated MAPK scaffold for the activation of JNK3. Science 2000; 290: 1574-1577.
37. Yang R, Trevillyan JM. c-Jun N-terminal kinase pathways in diabetes. Int J Biochem Cell Biol 2008; 40: 2702-2706.
38. Cheng X, Gao W, Dang Y, et al. Both ERK/MAPK and TGF-Beta/Smad signaling pathways play a role in the kidney fibrosis of diabetic mice accelerated by blood glucose fluctuation. J Diabetes Res 2013; 2013: 463740-463748.
39. Gorin Y, Ricono JM, Wagner B, et al. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. Biochem J 2004; 381: 231-239.
40. Turner NA, Ball SG, Balmforth AJ. The mechanism of angiotensin II-induced extracellular signal-regulated kinase-1/2 activation is independent of angiotensin AT(1A) receptor internalisation. Cell Signal 2001; 13: 269-277.
41. Long DA, Price KL, Herrera-Acosta J, Johnson RJ. How does angiotensin II cause renal injury? Hypertension 2004; 43: 722-723.
42. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun 2002; 290: 177-184.
43. Lin CL, Wang JY, Ko JY, Huang YT, Kuo YH, Wang FS. Dickkopf-1 promotes hyperglycemia-induced accumulation of mesangial matrix and renal dysfunction. J Am Soc Nephrol 2010; 21: 124-135.
44. Li JH, Wang W, Huang XR, et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004; 164: 1389-1397.
45. Toyoda M, Suzuki D, Honma M, et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 2004; 66: 1107-1114.
46. Huttunen HJ, Kuja-Panula J, Rauvala H. Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation. J Biol Chem 2002; 277: 38635-38646.
47. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 2000; 97: 8015-8020.
48. Bottinger EP. TGF-beta in renal injury and disease. Semin Nephrol 2007; 27: 309-320.
49. Sharma K, McGowan TA. TGF-beta in diabetic kidney disease: role of novel signaling pathways. Cytokine Growth Factor Rev 2000; 11: 115-123.
50. Lan HY. Transforming growth factor-beta/Smad signalling in diabetic nephropathy. Clin Exp Pharmacol Physiol 2012; 39: 731-738.
51. Lan HY, Chung AC. TGF-beta/Smad signaling in kidney disease. Semin Nephrol 2012; 32: 236-243.
52. Sharma K, Ziyadeh FN. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Semin Nephrol 1997; 17: 80-92.
53. Yang J, Zeng Z, Wu T, Yang Z, Liu B, Lan T. Emodin attenuates high glucose-induced TGF-beta1 and fibronectin expression in mesangial cells through inhibition of NF-kappaB pathway. Exp Cell Res 2013; 319: 3182-3189.
54. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kidney Int 1999; 56: 393-405.
55. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 2008; 13: 4984-4992.
56. Chen HY, Huang XR, Wang W, et al. The protective role of Smad7 in diabetic kidney disease: mechanism and therapeutic potential. Diabetes 2011; 60: 590-601.
57. Iglesias-de LCM, Ziyadeh FN, Isono M, et al. Effects of high glucose and TGF-beta1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int 2002; 62: 901-913.
58. Cha DR, Kim NH, Yoon JW, et al. Role of vascular endothelial growth factor in diabetic nephropathy. Kidney Int Suppl 2000; 77: S104-S112.
59. Senthil D, Choudhury GG, McLaurin C, Kasinath BS. Vascular endothelial growth factor induces protein synthesis in renal epithelial cells: a potential role in diabetic nephropathy. Kidney Int 2003; 64: 468-479.
60. Chung AC, Zhang H, Kong YZ, et al. Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 2010; 21: 249-260.
61. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
62. Hill C, Flyvbjerg A, Gronbaek H, et al. The renal expression of transforming growth factor-beta isoforms and their receptors in acute and chronic experimental diabetes in rats. Endocrinology 2000; 141: 1196-1208.
63. Peng F, Wu D, Gao B, et al. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008; 57: 1683-1692.
64. Eid AA, Gorin Y, Fagg BM, et al. Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 2009; 58: 1201-1211.
65. Mehta D, Rahman A, Malik AB. Protein kinase C-alpha signals rho-guanine nucleotide dissociation inhibitor phosphorylation and rho activation and regulates the endothelial cell barrier function. J Biol Chem 2001; 276: 22614-22620.
66. Sawada N, Itoh H, Yamashita J, et al. cGMP-dependent protein kinase phosphorylates and inactivates RhoA. Biochem Biophys Res Commun 2001; 280: 798-805.
67. Axelsson J, Rippe A, Rippe B. Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats. Am J Physiol Renal Physiol 2010; 298: F1306-F1312.
68. Komers R, Oyama TT, Beard DR, et al. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int 2011; 79: 432-442.
69. Kikuchi Y, Yamada M, Imakiire T, et al. A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats. J Endocrinol 2007; 192: 595-603.
70. Kolavennu V, Zeng L, Peng H, Wang Y, Danesh FR. Targeting of RhoA/ROCK signaling ameliorates progression of diabetic nephropathy independent of glucose control. Diabetes 2008; 57: 714-723.
71. Xie X, Peng J, Chang X, et al. Activation of RhoA/ROCK regulates NF-kappaB signaling pathway in experimental diabetic nephropathy. Mol Cell Endocrinol 2013; 369: 86-97.
72. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int 2003; 64: 2009-2019.
73. Jiang Q, Liu P, Wu X, et al. Berberine attenuates lipopolysaccharide-induced extracelluar matrix accumulation and inflammation in rat mesangial cells: involvement of NF-kappaB signaling pathway. Mol Cell Endocrinol 2011; 331: 34-40.
74. Kendellen MF, Bradford JW, Lawrence CL, Clark KS, Baldwin AS. Canonical and non-canonical NF-kappaB signaling promotes breast cancer tumor-initiating cells. Oncogene 2013;33: 1297-1305.
75. Salminen A, Huuskonen J, Ojala J, Kauppinen A, Kaarniranta K, Suuronen T. Activation of innate immunity system during aging: NF-kB signaling is the molecular culprit of inflamm-aging. Ageing Res Rev 2008; 7: 83-105.
76. Huang W, Xu L, Zhou X, et al. High glucose induces activation of NF-kappaB inflammatory signaling through IkappaBalpha sumoylation in rat mesangial cells. Biochem Biophys Res Commun 2013; 438: 568-574.
77. Yang Y, Xia F, Hermance N, et al. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol 2011; 31: 2774-2786.
78. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-759.
79. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 765-776.
80. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10: 1105-1137.
81. Ho C, Lee PH, Hsu YC, Wang FS, Huang YT, Lin CL. Sustained Wnt/beta-catenin signaling rescues high glucose induction of transforming growth factor-beta1-mediated renal fibrosis. Am J Med Sci 2012; 344: 374-382.
82. Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia 2008; 51: 1771-1780.
83. Kanda S, Miyata Y, Kanetake H. T-cell factor-4-dependent up-regulation of fibronectin is involved in fibroblast growth factor-2-induced tube formation by endothelial cells. J Cell Biochem 2005; 94: 835-847.
84. Niehrs C. The complex world of WNT receptor signalling. Nat Rev Mol Cell Biol 2012; 13: 767-779.
85. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC. Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290: F762-F768.
86. Berthier CC, Zhang H, Schin M, et al. Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 2009; 58: 469-477.
87. Amiri F, Shaw S, Wang X, et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 2002; 61: 1605-1616.
88. Beisswenger PJ, Drummond KS, Nelson RG, Howell SK, Szwergold BS, Mauer M. Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress. Diabetes 2005; 54: 3274-3281.
89. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB. Inhibition of the Jak/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 2002; 51: 3505-3509.
90. Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ Res 2010; 106: 1319-1331.
91. Tossidou I, Starker G, Kruger J, et al. PKC-alpha modulates TGF-beta signaling and impairs podocyte survival. Cell Physiol Biochem 2009; 24: 627-634.
92. Chuang TD, Guh JY, Chiou SJ, et al. Phosphoinositide 3-kinase is required for high glucose-induced hypertrophy and p21WAF1 expression in LLC-PK1 cells. Kidney Int 2007; 71: 867-874.
93. Wei J, Zhang Y, Luo Y, et al. Aldose reductase regulates miR-200a-3p/141-3p to coordinate Keap1-Nrf2, Tgfbeta1/2, and Zeb1/2 signaling in renal mesangial cells and the renal cortex of diabetic mice. Free Radic Biol Med 2014; 67: 91-102.
94. Dunlop M. Aldose reductase and the role of the polyol pathway in diabetic nephropathy. Kidney Int Suppl 2000; 77: S3-S12.
95. Brosius FC, Heilig CW. Glucose transporters in diabetic nephropathy. Pediatr Nephrol 2005; 20: 447-451.
96. Oates PJ. Aldose reductase inhibitors and diabetic kidney disease. Curr Opin Investig Drugs 2010; 11: 402-417.
97. Lloberas N, Cruzado JM, Franquesa M, et al. Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J Am Soc Nephrol 2006; 17: 1395-1404.
98. Wagener FA, Dekker D, Berden JH, Scharstuhl A, van der Vlag J. The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 2009; 14: 1451-1458.
99. Brezniceanu ML, Lau CJ, Godin N, et al. Reactive oxygen species promote caspase-12 expression and tubular apoptosis in diabetic nephropathy. J Am Soc Nephrol 2010; 21: 943-954.
100. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. Nat Rev Cancer 2005; 5: 51-63.
101. Peng L, Yang J, Ning C, et al. Rhein inhibits integrin-linked kinase expression and regulates matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio in high glucose-induced epithelial-mesenchymal transition of renal tubular cell. Biol Pharm Bull 2012; 35: 1676-1685.
102. Yan Q, Sui W, Xie S, et al. Expression and role of integrin-linked kinase and collagen IV in human renal allografts with interstitial fibrosis and tubular atrophy. Transpl Immunol 2010; 23: 1-5.
103. Forbes JM, Bonnet F, Russo LM, et al. Modulation of nephrin in the diabetic kidney: association with systemic hypertension and increasing albuminuria. J Hypertens 2002; 20: 985-992.
104. Lewko B, Bryl E, Witkowski JM, Latawiec E, Angielski S, Stepinski J. Mechanical stress and glucose concentration modulate glucose transport in cultured rat podocytes. Nephrol Dial Transplant 2005; 20: 306-311.
105. Dessapt C, Baradez MO, Hayward A, et al. Mechanical forces and TGFbeta1 reduce podocyte adhesion through alpha3beta1 integrin downregulation. Nephrol Dial Transplant 2009; 24: 2645-2655.
106. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000; 57: 405-413.
107. Huang K, Liu W, Lan T, et al. Berberine reduces fibronectin expression by suppressing the S1P-S1P2 receptor pathway in experimental diabetic nephropathy models. PLoS One 2012; 7: e43874-e43883.